Bioinformatics and immunoinformatics to support COVID‐19 vaccine development
Stephanie Ishack, Shari R. Lipner
Abstract
Severe acute respiratory syndrome coronavirus 2 has infected over 109 000 000 people with 2 423 443 deaths as of February 17, 2021. Currently, there are no approved or consistently effective treatments, and conventional vaccines may take several years for development and testing. In silico methods of bioinformatics, vaccinogenomics, immunoinformatics, structural biology, and molecular simulations can be used for more rapid and precise vaccine design. This paper highlights two major immunoinformatics strategies that are used in designing novel and effective vaccines and therapeutics: reverse vaccinology and structural vaccinology.
Topics & Concepts
Reverse vaccinologyCoronavirus disease 2019 (COVID-19)In silicoVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCoronavirusComputational biologyBiologyMedicineBioinformaticsInfectious disease (medical specialty)GeneticsPathologyGeneOutbreakDiseasevaccines and immunoinformatics approachesSARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune Responses